cidofovir

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Excreted mostly unchanged by the kidneys.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity to cidofovir, probenecid, or sulfonamides;
Serum creatinine >1.5 mg/dL, CCr ≤55 mL/min, or urine protein ≥100 mg/dL (≥2+ proteinuria)
;
OB:
Pregnancy
;
Lactation: Breastfeeding not recommended for women with HIV.

Use Cautiously in:

Pedi: Safety and effectiveness not established in children.

Exercise Extreme Caution in:

Any condition or medication that ↑ the risk of dehydration
.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: alopecia, rash

EENT: ↓intraocular pressure, hearing loss, iritis, ocular hypotony, uveitis

F and E: ↓serum bicarbonate

GI: abdominal pain, nausea, vomiting, anorexia, diarrhea, HEPATOTOXICITY, PANCREATITIS

GU: proteinuria, RENAL FAILURE

Hemat:

neutropenia

, anemia

Metab: METABOLIC ACIDOSIS

Neuro: headache, weakness

Resp: dyspnea, pneumonia

Misc: chills, fever, infection

Interactions ⬆ ⬇

Drug-drug:

↑risk of nephrotoxicity with aminoglycosides, amphotericin B, foscarnet, and pentamidine; avoid concurrent use and wait 7 days after giving other nephrotoxic agents.

Route/Dosage ⬆ ⬇

IV (Adults ): 5 mg/kg once weekly for 2 wk, followed by 5 mg/kg every 2 wk.

Renal Impairment

IV (Adults ):
↑in serum creatinine of 0.3–0.4 mg/dL: ↓dose to 3 mg/kg; discontinue if serum creatinine ↑≥0.5 mg/dL over baseline.

Availability ⬆ ⬇

(Generic available)

Solution for injection: 75 mg/mL

Assessment ⬆ ⬇

Monitor vision for progression of CMV retinitis. Monitor ocular symptoms, intraocular pressure, and visual acuity periodically.
Antiemetics and administration after a meal may ↓ nausea and vomiting associated with probenecid. If allergic reactions occur in association with probenecid, pretreatment with antihistamines or acetaminophen should be considered.
Monitor vital signs periodically. May cause fever, hypotension, and tachycardia. Monitor patients for early signs and symptoms of infection.

Lab Test Considerations:

Renal function, measured by serum creatinine and urine protein, must be monitored within 48 hr before each dose and throughout cidofovir therapy. In patients with proteinuria, administer IV hydration and repeat urine protein test. If renal function deteriorates, dose modification or temporary discontinuation should be considered.
- Monitor WBC before each dose. May cause neutropenia
  .
- May cause hyperglycemia, hyperlipemia, hypocalcemia, hypokalemia, and ↑ alkaline phosphatase, AST, and ALT.

Implementation ⬆ ⬇

Cidofovir is only indicated for the treatment of CMV retinitis in patients with HIV. It should not be used for the treatment of other CMV infections.
Probenecid and saline prehydration must be given with each dose of cidofovir to minimize renal toxicity. Probenecid must be administered 2 g PO 3 hr before cidofovir infusion and then 1 g given 2 hr and 8 hr after completion of cidofovir infusion. Prehydration with 1 L of 0.9% NaCl must be given over 1–2 hr before cidofovir infusion. A 2nd liter over 1–3 hr is recommended concurrently with or after cidofovir infusion.

IV Administration:

Intermittent Infusion: Diluent: Dilute in 100 mL of 0.9% NaCl. Solution is stable for 24 hr if refrigerated. Allow refrigerated solution to return to room temperature before administration.
Rate: Administer over 1 hr.
Y-Site Incompatibility: Do not administer other drugs through same IV line.

Patient/Family Teaching ⬆ ⬇

Inform patient that cidofovir is not a cure for CMV retinitis and that retinitis may continue to progress during and after therapy.
Inform patient that concurrent antiretroviral therapy may be continued. However, zidovudine therapy should be temporarily discontinued or ↓ by 50% on the days of cidofovir therapy because of the effects of probenicid on zidovudine.
Advise patient of the possibility of renal toxicity from cidofovir. Emphasize the importance of routine lab tests to monitor renal function.
Discuss with patient the possibility of hair loss. Explore coping strategies.
Advise patients to have routine ophthalmologic exams after cidofovir therapy.
Rep:
May cause fetal harm. Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected and to avoid breastfeeding during therapy. Advise women of reproductive potential to use contraception during and for 1 mo after therapy. Men should use barrier contraception during and for 3 mo after therapy.

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇